Axitinib

Licensed by Pfizer Catalog No.S1005 Synonyms: AG 013736

Axitinib Chemical Structure

Molecular Weight(MW): 386.47

Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 120 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Representative confocal image (10 x objective) of individual spheroids fixed, sectioned, and then stained for vimentin (green) and DNA (DAPI, blue). Vimentin protein expression from sections quantitated from multiple replicate spheroid treatments with U0126 and axitinib using ImageJ software.

    J Biomol Screen, 2011,16: 141-154. Axitinib purchased from Selleck.

    VimPro-Fluc activity in spheroids after 72-h treatment with control modulators of epithelial-mesenchymal transition (EMT) normalized to spheroid viability and compared to vimentin protein expression using Western blot analysis.

    J Biomol Screen, 2011,16: 141-154. Axitinib purchased from Selleck.

  • Secondary assay development. The invasive potential of MDA-MB-231 spheroids was measured using modified Boyden chambers coated with Matrigel™. Invading cells were fixed, stained with DAPI, and quantified by fluorescence microscopy using 5 random fields per filter insert in triplicate. U0126, PF2341066, axitinib, and PKC412 inhibited the invasive potential of MDA-MB-231 spheroids by ~90% as compared to untreated spheroids (UT). ***p ≤ 0.001. IGF1R and dasatinib displayed no statistical difference as compared to UT MDA-MB-231 spheroids.

    J Biomol Screen 2011 16, 141-154. Axitinib purchased from Selleck.

    Axitinib treatment blocks VEGFR2 phosphorylation.

    HUVECs were starved O/N in EBM-2 basal medium with 1% FBS and antibiotic. Cells were pre-treated with Axitinib at 0.1, 1 and 10 nM concentrations. VEGF stimulation was 50 ng/ml for 10 minutes before cells were collected and protein isolated for immunoprecipitation with VEGFR2 followed by immunoblotting with VEGFR-2 and phospho-VEGFR-2.

     

     

    Dr. Cheri Pasch of UW Madison. Axitinib purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.
Features Superior as second-line therapy relative to sorafenib (current standard-of-care).
Targets
VEGFR1/FLT1 [1]
(Porcine aorta endothelial cells)
VEGFR2/Flk1 [1]
(Porcine aorta endothelial cells)
VEGFR2/KDR [1]
(Porcine aorta endothelial cells)
VEGFR3 [1]
(Porcine aorta endothelial cells)
PDGFRβ [1]
(Porcine aorta endothelial cells)
0.1 nM 0.18 nM 0.2 nM 0.1 nM-0.3 nM 1.6 nM
In vitro

Axitinib could block the cellular autophosphorylation of VEGFR and VEGF-mediated endothelial cell viability, tube formation, and downstream signaling. Axitinib inhibits the proliferation of variable cell lines with IC50 of >10,000 nM (IGR-N91), 849 nM (IGR-NB8), 274 nM (SH-SY5Y) and 573 nM (non-VEGF stimulated HUVEC). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell M1rlcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TPOWlEPTB;MD6wNFAxPTF|IN88US=> M33WRnNCVkeHUh?=
NCI-H1703 MnftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPXTWM2OD1yLkCwNFkxOiEQvF2= M2PhenNCVkeHUh?=
KASUMI-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1W1fWlEPTB;MD6wNFY5OiEQvF2= MULTRW5ITVJ?
CGTH-W-1 NX\TRoNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkD5TWM2OD1yLkCwO|IzKM7:TR?= NIiyfWFUSU6JRWK=
A204 NUnVO2dNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7uXXE2UUN3ME2wMlAxQTl{IN88US=> NYXWUpQ1W0GQR1XS
HOP-62 NHPFZopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTBwMUC4N|Yh|ryP NH;sRVdUSU6JRWK=
H-EMC-SS NWDKO49ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TYN2lEPTB;MD6xNVAxPSEQvF2= MYTTRW5ITVJ?
KU812 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWq4ZYdLUUN3ME2wMlE3PTd5IN88US=> MVjTRW5ITVJ?
EM-2 MorXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33nNGlEPTB;MD6xOlgyPiEQvF2= NUKzd21sW0GQR1XS
LAMA-84 NHLpfm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfTTWM2OD1yLkG3OlY2KM7:TR?= NVW0d2RuW0GQR1XS
JAR NVKzTmlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fBcWlEPTB;MD6yN|k5QSEQvF2= MWPTRW5ITVJ?
G-361 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\w[o5KSzVyPUCuN|I{OjVizszN Mny5V2FPT0WU
KG-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXUTpNKSzVyPUCuN|c3PDJizszN M2Dk[3NCVkeHUh?=
BV-173 MkLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3LTmc5UUN3ME2wMlM6OzJizszN MmW4V2FPT0WU
K5 NYXZO4FwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnDenRKSzVyPUCuOFIyOjdizszN MkO3V2FPT0WU
MEG-01 MnPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH6zZ3VKSzVyPUCuOFI{PjFizszN MnHmV2FPT0WU
MFM-223 NVvBUJp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1uzOGlEPTB;MD60OFc4PiEQvF2= M1LWXXNCVkeHUh?=
BE-13 MknKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LIWWlEPTB;MD61NVAxQCEQvF2= MXHTRW5ITVJ?
NEC8 Mn\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XIWmlEPTB;MD63NlEyOyEQvF2= M4ToenNCVkeHUh?=
SW756 NE\JfXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXMfFdsUUN3ME2wMlk6QDR4IN88US=> NHTYO2ZUSU6JRWK=
A2780 Ml;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGj6SmxKSzVyPUGuNFEyPDZizszN M2LKUXNCVkeHUh?=
NB14 NXH6SG42T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDk[2M4UUN3ME2xMlAyQDBzIN88US=> MnXoV2FPT0WU
H4 MoPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTFwME[0NlIh|ryP MkT2V2FPT0WU
SK-OV-3 NG\3UIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYK0cXptUUN3ME2xMlA3PjN|IN88US=> NFLiXoRUSU6JRWK=
AN3-CA NEXRTXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXZdnFUUUN3ME2xMlA5Ozh7IN88US=> NXHWe4x5W0GQR1XS
A427 M2S5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTFwMUCzPFEh|ryP NY\DTFM6W0GQR1XS
ES7 NH3FdXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LMO2lEPTB;MT6xNVM{PCEQvF2= Ml;ZV2FPT0WU
AGS NInReYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HQfWlEPTB;MT6xNVM6PSEQvF2= NYXPXYV4W0GQR1XS
G-402 NFPCepRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\xTWM2OD1zLkG0Olk1KM7:TR?= NULJRoRUW0GQR1XS
ES5 NYTmVnFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTFwMUeyOFgh|ryP Mn3OV2FPT0WU
DEL NXPlOo1VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzyTWM2OD1zLkK1OFU4KM7:TR?= NVy3T2NVW0GQR1XS
NB10 NHjGXlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFf3WYdKSzVyPUGuN|I2PTdizszN MVrTRW5ITVJ?
NCI-H1581 MlPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrJSWhrUUN3ME2xMlM6ODR{IN88US=> MoPsV2FPT0WU
D-566MG NXzhO|dNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnyV49KSzVyPUGuOFA3QDNizszN MXrTRW5ITVJ?
LXF-289 NUHKRldqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnm4TWM2OD1zLkSzPVk3KM7:TR?= NUnw[FlvW0GQR1XS
BT-549 MljZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWr4V2p[UUN3ME2xMlU3QTB7IN88US=> NUfMOG5OW0GQR1XS
NKM-1 M2rVW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXP1T5hkUUN3ME2xMlYxPTV4IN88US=> MVfTRW5ITVJ?
SW780 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLFTWM2OD1zLk[1NVU5KM7:TR?= MYrTRW5ITVJ?
NCI-H292 M3W2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLTdmZKSzVyPUGuOlY{QDNizszN NXHwelE{W0GQR1XS
HMV-II NHX2XFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPtb|NxUUN3ME2xMlcxPDh6IN88US=> Ml3FV2FPT0WU
ALL-PO MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTDTWM2OD1zLkiwNFE2KM7:TR?= M3XXTnNCVkeHUh?=
UACC-257 NWTtepZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHixNJZKSzVyPUGuPFIyPjNizszN MYHTRW5ITVJ?
PA-1 NYfMfnZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoKxTWM2OD1zLkiyO|I2KM7:TR?= NULxW|JnW0GQR1XS
HD-MY-Z NHnDT49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LMWGlEPTB;MT64OlI5OSEQvF2= NHrzZVhUSU6JRWK=
HSC-4 M2\IWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3TTYZsUUN3ME2xMlk{QDN7IN88US=> NUi0bms4W0GQR1XS
GCT M1PvTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPRU4dtUUN3ME2yMlAxQTF4IN88US=> MlnMV2FPT0WU
RT-112 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPObox{UUN3ME2yMlE{PDJ2IN88US=> MXTTRW5ITVJ?
A172 Mn3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWX3T2pNUUN3ME2yMlE{PjB4IN88US=> NGPLeWNUSU6JRWK=
HCE-T MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVG4SGFIUUN3ME2yMlIxPTl6IN88US=> NIrrNJZUSU6JRWK=
YH-13 M1zUNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\acWlEPTB;Mj6yNVY4OSEQvF2= MkXoV2FPT0WU
DK-MG NEH4VYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrlTWM2OD1{LkKzPFM1KM7:TR?= NVvOdmtWW0GQR1XS
ACN NET1OY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XwVmlEPTB;Mj6yN|g4PSEQvF2= NETOSIdUSU6JRWK=
VA-ES-BJ NGX2TWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTJwMkS5OVch|ryP NG[4SnZUSU6JRWK=
L-363 NIXHWpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rURmlEPTB;Mj6yPFA3OSEQvF2= M3TQd3NCVkeHUh?=
HuH-7 M37KVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnxXlJ1UUN3ME2yMlQzOTZ3IN88US=> NGLPVmhUSU6JRWK=
A4-Fuk NVf5ZYU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnTPJJKSzVyPUKuOFcyPjhizszN NEe3cmFUSU6JRWK=
T-24 Mlf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTPTVNKSzVyPUKuOFgxOzdizszN MX7TRW5ITVJ?
GOTO M176Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PPeWlEPTB;Mj61N|AyOyEQvF2= MnWwV2FPT0WU
MV-4-11 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrjd4xKSzVyPUKuOVkyPjlizszN MnvvV2FPT0WU
DMS-114 NXTGZplpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7ZTWM2OD1{Lk[2N|Q2KM7:TR?= NYPqUIZYW0GQR1XS
MHH-NB-11 NVnLV4xiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGSzUJFKSzVyPUKuO|AzQTlizszN NWnFZXJUW0GQR1XS
CHP-212 Mlf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLvTWM2OD1{LkiyNFkyKM7:TR?= MYDTRW5ITVJ?
DMS-273 Mke0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDqboFKSzVyPUKuPVAzODdizszN MmnZV2FPT0WU
SF295 NWHoZm9{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkK5TWM2OD1|LkCyOVk4KM7:TR?= MVnTRW5ITVJ?
NCI-H1563 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPnNJlxUUN3ME2zMlE2ODB3IN88US=> MVHTRW5ITVJ?
NCI-H446 NFvYe|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\DTmlEPTB;Mz6yNlgxPSEQvF2= M1jGc3NCVkeHUh?=
HCC1806 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2G1e2lEPTB;Mz6yO|Y2PyEQvF2= Mly4V2FPT0WU
SF126 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTNwM{CwNVch|ryP NYXnZoVwW0GQR1XS
SW982 NHjMN3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfVTWM2OD1|LkOzPFc2KM7:TR?= M3X0PHNCVkeHUh?=
ES8 NEXoOlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH:1NGFKSzVyPUOuN|Q6QTlizszN MV7TRW5ITVJ?
SCC-4 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XxcWlEPTB;Mz61NFM6PiEQvF2= NFO4TVNUSU6JRWK=
RPMI-8226 NWHocZNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzPTWM2OD1|Lk[yOlE3KM7:TR?= Ml;CV2FPT0WU
EW-11 NGOwOolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nrdmlEPTB;Mz62N|AzOiEQvF2= NVi1NI16W0GQR1XS
COR-L105 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLsTWM2OD1|Lk[zN|M1KM7:TR?= MWDTRW5ITVJ?
ES1 M3\hcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoiyTWM2OD1|LkizNFk1KM7:TR?= MUTTRW5ITVJ?
KMOE-2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTNwOUG4NFgh|ryP MWnTRW5ITVJ?
ABC-1 NEf2dohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPBTWM2OD1|LkmzPVEyKM7:TR?= NI\2PG5USU6JRWK=
NCI-H526 NHK0UYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTNwOUmxNlYh|ryP NGi2ZXlUSU6JRWK=
HCC1395 NXrvcotOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTNwOUm0PFQh|ryP M2PSRnNCVkeHUh?=
DU-145 MmDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTaUWJoUUN3ME20MlEzQDJ3IN88US=> M{fZZXNCVkeHUh?=
JEG-3 MnnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljoTWM2OD12LkG1PVE3KM7:TR?= NUO4VWNMW0GQR1XS
HCC1187 M3rqOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\IdWlEPTB;ND6yNVU6PyEQvF2= NHXkZ2lUSU6JRWK=
LC-2-ad NVfvNmpKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTRwMkKxO|ch|ryP NWWyW|VMW0GQR1XS
ONS-76 MmDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;BZWlEPTB;ND6yOFE6OiEQvF2= NW\0fHB5W0GQR1XS
CAL-27 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTRwMkSzOFQh|ryP MknaV2FPT0WU
8-MG-BA M2LzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTRwMk[2OVgh|ryP NIjVZ41USU6JRWK=
HGC-27 M1vTXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInHeG5KSzVyPUSuNlk3PiEQvF2= M1\YW3NCVkeHUh?=
Hs-578-T NYfEXmJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\MVnhKSzVyPUSuN|E1PjhizszN MYrTRW5ITVJ?
EW-1 Mn7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXX4PYRsUUN3ME20MlU{ODF2IN88US=> NV\vbYI{W0GQR1XS
SW1573 MnG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DNN2lEPTB;ND61OVE3OyEQvF2= NHnTSG1USU6JRWK=
SNU-423 NFjReo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jEdGlEPTB;ND62NFc6KM7:TR?= MlPSV2FPT0WU
HOS M4T6eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEP0WWpKSzVyPUSuOlk4PyEQvF2= NInaVoFUSU6JRWK=
LB1047-RCC NV75cVFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzWdlNKSzVyPUSuPFE1OThizszN NWrYcXBNW0GQR1XS
ChaGo-K-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzwdJhYUUN3ME20Mlg6ODR6IN88US=> NXjMe4JUW0GQR1XS
A3-KAW Mnq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jVW2lEPTB;ND65O|M2OiEQvF2= NHP2blFUSU6JRWK=
CAS-1 NEfoT|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml65TWM2OD12Lkm5PVA5KM7:TR?= MWrTRW5ITVJ?
NBsusSR M1rxWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\GXWlEPTB;NT6wN|UyPCEQvF2= NG\q[IpUSU6JRWK=
KM12 M{jSe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTLd2ZVUUN3ME21MlI6QDJ5IN88US=> NH;zfJZUSU6JRWK=
NCI-H1155 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnibXZKSzVyPUWuN|gyQDVizszN NFnDfnJUSU6JRWK=
EFM-19 NWrIRYZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn[5TWM2OD13LkSxO|M4KM7:TR?= NIXibY9USU6JRWK=
D-392MG M4LacWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjMNodKSzVyPUWuOVc5PDlizszN MUjTRW5ITVJ?
JVM-3 NWj2[21RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTVwN{KzNlUh|ryP MYDTRW5ITVJ?
EW-16 NVHJZ3BzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2S0WmlEPTB;NT63OVU5OyEQvF2= Mlm3V2FPT0WU
KARPAS-45 NESzZ5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF31TpNKSzVyPUWuPFQ{OjVizszN NEj0e2dUSU6JRWK=
NCI-H28 NIOx[5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjkeI1KSzVyPUWuPFc6OThizszN NGWyRo9USU6JRWK=
COLO-829 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHRPYhGUUN3ME21MlkyPTB2IN88US=> NHPqXY5USU6JRWK=
KM-H2 NIDadXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoGyTWM2OD13LkmyN|k2KM7:TR?= MlLqV2FPT0WU
NCI-H82 NV\pXWliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTVwOUK3O|Eh|ryP MYjTRW5ITVJ?
OAW-42 NYnx[4I{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjTNHBKSzVyPUWuPVg5OjFizszN NUK0dG4zW0GQR1XS
A704 NFG1VmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zDUGlEPTB;Nj6xNFU4PCEQvF2= NWnMTmhSW0GQR1XS
NCI-H1048 M{nFTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTKbnZoUUN3ME22MlExPTl7IN88US=> NHTTZWhUSU6JRWK=
LOXIMVI NGHLSIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fnUGlEPTB;Nj6xNVI1QCEQvF2= MoizV2FPT0WU
MKN45 NXvhNpc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTZwMk[wNVYh|ryP M4DsOnNCVkeHUh?=
D-502MG MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPuTWM2OD14LkK4PFU4KM7:TR?= MnTCV2FPT0WU
HUTU-80 M3\se2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTZwNEG2PFgh|ryP NF\GdHBUSU6JRWK=
S-117 NWDzPY1GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTZwNUCyOlch|ryP NXjYWJN5W0GQR1XS
HCC1569 M1eyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfHTWM2OD14LkWzO|M4KM7:TR?= NXHDSZlUW0GQR1XS
J-RT3-T3-5 NYHNZoxCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrqTWM2OD14LkW0OVczKM7:TR?= MXvTRW5ITVJ?
OC-314 NYDGboJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXIVJRKSzVyPU[uPVEyPTlizszN NFTLPZZUSU6JRWK=
SNU-449 NITBS4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlX1TWM2OD15LkCxNFczKM7:TR?= MVnTRW5ITVJ?
NCI-H720 MlHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLTcnhSUUN3ME23MlE6OzR3IN88US=> M{LPU3NCVkeHUh?=
KP-N-YS MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTdwMkC3NkDPxE1? NXHrOYw4W0GQR1XS
IGROV-1 MknlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXpW2dKSzVyPUeuN|I{QDZizszN M3XSb3NCVkeHUh?=
SK-PN-DW MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTdwNEixOUDPxE1? Mn\mV2FPT0WU
HCC1419 NIHidnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUmzfVBXUUN3ME23MlU{KM7:TR?= MkLxV2FPT0WU
HAL-01 M3q2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLqTWM2OD15Lk[wOlQ1KM7:TR?= NIjZd5lUSU6JRWK=
HCC2998 NX;kRWdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn74TWM2OD15Lk[wO|Q{KM7:TR?= M3j2NnNCVkeHUh?=
SK-N-FI NUjudG1CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTdwNkOwN|Mh|ryP MWfTRW5ITVJ?
GI-ME-N M3\jeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonrTWM2OD15Lk[0PVM1KM7:TR?= NXPNVWhTW0GQR1XS
SW1088 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknsTWM2OD15Lk[1PFI3KM7:TR?= NIj2[2pUSU6JRWK=
IA-LM NXf4SIhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTdwNki2NVMh|ryP NF7XemRUSU6JRWK=
SK-NEP-1 NH\lXnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnBR3ZnUUN3ME23MlY6PjFizszN Ml3oV2FPT0WU
MDA-MB-415 M{\NPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHsSIpjUUN3ME23Mlg6OTh4IN88US=> MWTTRW5ITVJ?
COLO-800 MoHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnFcWtKSzVyPUeuPVQ1QTJizszN MnfQV2FPT0WU
NCI-H2228 Mn22S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHm1Z3NKSzVyPUiuNVU4QDNizszN M2LUWnNCVkeHUh?=
D-423MG M2LZR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfBZVRvUUN3ME24MlIyPzJizszN NGTTSVRUSU6JRWK=
TE-1 NX3KNYdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRThwNESzNVYh|ryP NV7ZdpZTW0GQR1XS
NOS-1 NFG0TYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3q2NWlEPTB;OD61NVU{PCEQvF2= MlzyV2FPT0WU
8505C MlywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnq2TWM2OD16Lk[0PFI1KM7:TR?= MWDTRW5ITVJ?
HEC-1 MorPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIexVGdKSzVyPUiuO|g1OzlizszN Mmq3V2FPT0WU
TE-11 M4Ts[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRThwOUm1OVEh|ryP M1PHSHNCVkeHUh?=
CTB-1 NEHvUGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHoTFVKSzVyPUmuNFE1OzNizszN NX\ENJBoW0GQR1XS
TGBC11TKB NF7PZWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrtR5pqUUN3ME25MlAzOjRzIN88US=> NI\Ne4VUSU6JRWK=
NB17 NILjOHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXUTWM2OD17LkG4PFch|ryP Mn74V2FPT0WU
Becker MmXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTlwNEG5OFQh|ryP NWXRO5ZjW0GQR1XS
SN12C M3\xWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoGzTWM2OD17LkS1NlM1KM7:TR?= NWjlbXZMW0GQR1XS
COLO-320-HSR MoTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TGO2lEPTB;OT62NFI{PyEQvF2= M{Kxc3NCVkeHUh?=
D-283MED NWfBS5drT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTlwNkOwO|Ih|ryP NELsc4NUSU6JRWK=
D-263MG NXjBbYV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DhbmlEPTB;OT64N|M5PCEQvF2= MYrTRW5ITVJ?
MEL-JUSO MlzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlz3TWM2OD17LkmwNVI4KM7:TR?= NIT4PVlUSU6JRWK=
T98G M1\qdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{D2WWlEPTB;OT65NFIxOyEQvF2= MYDTRW5ITVJ?
HLE MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTlwOUC5NFkh|ryP MmroV2FPT0WU
Ca9-22 NXHKb3pZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTFyLkC2OlUh|ryP NWj5cZp6W0GQR1XS
OS-RC-2 NUmxNHJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTFyLkGwOFUh|ryP MkLJV2FPT0WU
T47D MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHvbFJIUUN3ME2xNE4yPTVizszN NHHIZWlUSU6JRWK=
GI-1 M{PTXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfkOoJTUUN3ME2xNE4{PTN|IN88US=> M3TrOXNCVkeHUh?=
NUGC-3 MkLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTFyLkS0NFIh|ryP Mn;OV2FPT0WU
MDA-MB-361 NWDhcJlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmniTWM2OD1zMD60OFMzKM7:TR?= MnzhV2FPT0WU
SCC-15 Mkf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFz5TotKSzVyPUGwMlQ4OThizszN M3[y[XNCVkeHUh?=
KS-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWe1fI9JUUN3ME2xNE43OzBzIN88US=> NEjxe3dUSU6JRWK=
CAL-12T Mn7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;4cGpKSzVyPUGwMlY{PjFizszN M2PBXnNCVkeHUh?=
OVCAR-4 Ml75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTFyLkewOlgh|ryP NF;MOIRUSU6JRWK=
HuP-T4 MkXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzvdXk1UUN3ME2xNU4xOzJ6IN88US=> MXvTRW5ITVJ?
NCI-H358 MlrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2W0cmlEPTB;MUGuNlY2PyEQvF2= NFrwRnpUSU6JRWK=
HO-1-N-1 NVzoeHM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlSwTWM2OD1zMT6zN|k5KM7:TR?= NX;3WFV4W0GQR1XS
NH-12 M1XMRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zYU2lEPTB;MUGuOVM4QCEQvF2= NUK5Z3psW0GQR1XS
MOLT-4 MnrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHiw[IJKSzVyPUGxMlU6QDVizszN NHvmeIxUSU6JRWK=
K-562 M33Tbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInKcXlKSzVyPUGxMlczPDhizszN NGH3WZBUSU6JRWK=
ES6 NUm4cZExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1ewZ2lEPTB;MUGuPFU5OSEQvF2= MlfsV2FPT0WU
RO82-W-1 NFq0dWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXFUpVKSzVyPUGxMlkxPjRizszN NUXOPZJMW0GQR1XS
Ramos-2G6-4C10 M{TxWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLaO|c1UUN3ME2xNU46OzJizszN MlvFV2FPT0WU
23132-87 NHjTfm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV22N5JIUUN3ME2xNk4xQDJzIN88US=> MkP6V2FPT0WU
A549 NXv0VpU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LrSmlEPTB;MUKuN|I5PSEQvF2= MnXOV2FPT0WU
NCI-H23 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFL2bW5KSzVyPUGyMlUxOjZizszN MV\TRW5ITVJ?
H9 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTF{LkW1O|ch|ryP NHzYWZdUSU6JRWK=
LB771-HNC NGOxSVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfLfVVvUUN3ME2xNk44PjVizszN MmTLV2FPT0WU
QIMR-WIL M1y3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLDWnB[UUN3ME2xNk45OjV6IN88US=> Mkj1V2FPT0WU
HSC-3 NUXHVZBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDS[HI6UUN3ME2xNk46Ojd4IN88US=> MWLTRW5ITVJ?
PFSK-1 M2\iR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTCXlBZUUN3ME2xNk46PTB5IN88US=> MkTWV2FPT0WU
ETK-1 NYK3cIZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTF|LkC3O|kh|ryP NEntZnNUSU6JRWK=
SW1710 NXvPcZRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTPTWM2OD1zMz6zOlQyKM7:TR?= M1TlXXNCVkeHUh?=
COLO-684 NWXHVZl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorlTWM2OD1zMz60OVQyKM7:TR?= MUDTRW5ITVJ?
RPMI-7951 NEDtZoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPRTWM2OD1zMz61NVM3KM7:TR?= NHj1WHdUSU6JRWK=
A101D NXn3eIx6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrhd49{UUN3ME2xN{42OzR7IN88US=> MnHRV2FPT0WU
KE-37 MkHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nzfmlEPTB;MUOuOVg5PyEQvF2= M{DOcHNCVkeHUh?=
SiHa MnTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTF|LkizOFYh|ryP MXjTRW5ITVJ?
NCI-H226 MofNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rqZWlEPTB;MUOuPFgxQCEQvF2= NVrEOWFDW0GQR1XS
DB MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInZbZZKSzVyPUGzMlk6OjhizszN MWHTRW5ITVJ?
HT-1197 M33PSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TiWmlEPTB;MUSuNFgxQSEQvF2= MmTTV2FPT0WU
SBC-5 Mnr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTF2LkGzOlIh|ryP NHTq[FNUSU6JRWK=
VMRC-RCZ MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nxS2lEPTB;MUSuOVc4PCEQvF2= MnezV2FPT0WU
697 MorrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2GwXGlEPTB;MUSuOlI4KM7:TR?= M4DuVXNCVkeHUh?=
OMC-1 NVXpVJVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTF2Lke4PFgh|ryP NFPBUpdUSU6JRWK=
SKG-IIIa NXTHcWxkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTF2LkiwNFEh|ryP NHLUPVRUSU6JRWK=
DOK M3nBW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTF2Lkm5N|Mh|ryP NEj5e5hUSU6JRWK=
NCI-H2029 NWXPU29tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTF3LkO2NFIh|ryP MVrTRW5ITVJ?
NCI-H2009 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTF3LkWwPVUh|ryP NY\LXWJiW0GQR1XS
LK-2 M4e3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHuNmVKSzVyPUG1MlY1PDlizszN NIDpSXFUSU6JRWK=
NCI-H661 NETJOlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXLTWM2OD1zNT65NFc2KM7:TR?= MnzoV2FPT0WU
GT3TKB M3GwPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPyXVBKSzVyPUG2MlA3PzZizszN NXXxN4x[W0GQR1XS
GP5d Mnj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF[wdJhKSzVyPUG2MlM1OiEQvF2= MWPTRW5ITVJ?
SK-MEL-2 NY\Gb4pXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTF4LkS0PFUh|ryP MUTTRW5ITVJ?
SK-UT-1 NWryWWFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfsOZFKSzVyPUG2MlU3PSEQvF2= MoXZV2FPT0WU
NB7 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPtTWM2OD1zNj62PVcyKM7:TR?= NI[0W41USU6JRWK=
NCI-H460 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vreWlEPTB;MU[uO|MzPiEQvF2= M3;5PHNCVkeHUh?=
8305C MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HaSWlEPTB;MU[uO|g4PyEQvF2= NHv5V|ZUSU6JRWK=
CaR-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTF4LkixNVEh|ryP MoHFV2FPT0WU
D-247MG NFqx[2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnLdIpKSzVyPUG2Mlg3OjVizszN MmfSV2FPT0WU
LoVo MnPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonwTWM2OD1zNj65OFg5KM7:TR?= NEHlcnRUSU6JRWK=
NCI-H2405 NETkTVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTMTWM2OD1zNz6xPVA5KM7:TR?= MX3TRW5ITVJ?
AU565 M{DhfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\wTWM2OD1zNz6yNlUh|ryP M{LGfnNCVkeHUh?=
OCI-AML2 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHiOGlKSzVyPUG3MlU{OTdizszN NWDDSnBmW0GQR1XS
22RV1 M1jZdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPKUHppUUN3ME2xO{42QDh2IN88US=> MlrGV2FPT0WU
HT-144 M1PBRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XqW2lEPTB;MUeuOlU6QCEQvF2= NF;5ZpZUSU6JRWK=
HuO9 NXHxenh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLD[2xGUUN3ME2xO{44ODNzIN88US=> MlfzV2FPT0WU
Daoy MnTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHCT|FKSzVyPUG3MlcyQDRizszN M3:5UHNCVkeHUh?=
SJRH30 NWm3TGZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XsNWlEPTB;MUeuPFQ5QSEQvF2= MX;TRW5ITVJ?
CHL-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTF5LkmyOFkh|ryP MoPEV2FPT0WU
J82 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPnTWM2OD1zNz65OlM2KM7:TR?= NHHyZ|lUSU6JRWK=
COR-L23 NVPNPZRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTF6LkCwNVEh|ryP M3zBT3NCVkeHUh?=
SNU-C2B NGj5bYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVixVmZUUUN3ME2xPE4zOjd4IN88US=> NIqwU5pUSU6JRWK=
NCI-H1770 Ml7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITGdHlKSzVyPUG4MlQ3OTVizszN MnLQV2FPT0WU
MHH-PREB-1 NHntW5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTF6LkW2PVch|ryP M1;WWnNCVkeHUh?=
ES3 NW\EXVVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlniTWM2OD1zOD61PFg{KM7:TR?= M{TsXXNCVkeHUh?=
MDA-MB-231 MmT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTjWnhwUUN3ME2xPE43PTB{IN88US=> NH7iOolUSU6JRWK=
MN-60 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nuOmlEPTB;MUmuNFU6OiEQvF2= MU\TRW5ITVJ?
EPLC-272H M3rsXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPxTHpKSzVyPUG5MlM4ODhizszN MVfTRW5ITVJ?
SW948 M{D1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvyfYVwUUN3ME2xPU4{QTN2IN88US=> NVrKNJBwW0GQR1XS
MOLT-13 NFz0dJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13vb2lEPTB;MUmuOFU1PiEQvF2= NUPROGZqW0GQR1XS
HL-60 NIj4UFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\nTWM2OD1{MD6yNVQyKM7:TR?= NIHSPFhUSU6JRWK=
CP50-MEL-B M{XOVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFj4bnlKSzVyPUKwMlQ4PDhizszN MoHGV2FPT0WU
NTERA-S-cl-D1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEG5WndKSzVyPUKwMlQ6PzhizszN NHPSZ4xUSU6JRWK=
KINGS-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3YbJJKSzVyPUKwMlc6PjdizszN M3m5XXNCVkeHUh?=
DOHH-2 NWTRVmpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\mdJhIUUN3ME2yNE46ODZizszN MV7TRW5ITVJ?
BB65-RCC NX30RppVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTYe5lKSzVyPUKwMlkzQDVizszN NGDPV3RUSU6JRWK=
NB12 M{O5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTJzLkCzPVQh|ryP Mn3DV2FPT0WU
KY821 NHLpdINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIK0TnRKSzVyPUKxMlU5OiEQvF2= MnTVV2FPT0WU
PSN1 NXj0XG1CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnr4TWM2OD1{MT62OFU{KM7:TR?= M3j3UnNCVkeHUh?=
EGI-1 NUjpcnVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\iNIJKSzVyPUKxMlc1PTRizszN MmDvV2FPT0WU
CTV-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTJ{LkOwN|Eh|ryP M17XT3NCVkeHUh?=
TI-73 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33uUGlEPTB;MkKuN|Q6QCEQvF2= MXnTRW5ITVJ?
LCLC-103H NHGwOGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfOTGNKSzVyPUKyMlQ4PTJizszN NFKyWopUSU6JRWK=
D-542MG MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHLTWM2OD1{Mj61OVU5KM7:TR?= MmPMV2FPT0WU
ATN-1 M2jvfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vOZWlEPTB;MkKuOlQ{QSEQvF2= MnTOV2FPT0WU
SK-MEL-1 M334R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXNZZdKSzVyPUKyMlg{PjhizszN NYnqVJQ5W0GQR1XS
HDLM-2 NXHVUnRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVmyOXdWUUN3ME2yN{4yPDd6IN88US=> NEjkR|JUSU6JRWK=
UM-UC-3 M1HtTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moi3TWM2OD1{Mz6xPVQ1KM7:TR?= MWfTRW5ITVJ?
NCI-H1573 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7SXHlKSzVyPUKzMlQ3QDFizszN M3XoUXNCVkeHUh?=
NCI-H520 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zjNmlEPTB;MkOuOFk1QCEQvF2= MmG0V2FPT0WU
ESS-1 NWXMTGd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{K2cGlEPTB;MkOuPFA2QSEQvF2= M3vtOHNCVkeHUh?=
COR-L88 NEezfFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfaTWM2OD1{Mz65OFc2KM7:TR?= M2O4XHNCVkeHUh?=
TGBC24TKB NHHvZ4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTJ2LkCzNVIh|ryP MnjyV2FPT0WU
HCC1937 NUnBWY1YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTJ2LkGg{txO NHuzTYZUSU6JRWK=
RS4-11 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPGbXJKSzVyPUK0MlE1OiEQvF2= M{nMTnNCVkeHUh?=
HCC38 NYnNelBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M323emlEPTB;MkSuNlM6PCEQvF2= M3z4RnNCVkeHUh?=
RPMI-2650 NXXuOGRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETxeVJKSzVyPUK0MlYyPjJizszN NIfXZ4hUSU6JRWK=
P12-ICHIKAWA M2fQZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjxfmNKSzVyPUK0MlYzPThizszN MXPTRW5ITVJ?
YAPC Mmq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jG[mlEPTB;MkSuPFIyPCEQvF2= MkLHV2FPT0WU
NB13 M4P5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLmPVN7UUN3ME2yOU4zPjFzIN88US=> NHvJfm1USU6JRWK=
SK-N-AS NV;FV2xVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTzTWM2OD1{NT64OVg1KM7:TR?= MXzTRW5ITVJ?
SK-N-DZ M3HmbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvXTWM2OD1{Nj6wOFkh|ryP MU\TRW5ITVJ?
LS-411N M136XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHL4WlVKSzVyPUK2MlIxOzhizszN NFTRW|BUSU6JRWK=
NCI-H810 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mon4TWM2OD1{Nj6zNVEzKM7:TR?= NHzK[VRUSU6JRWK=
NCI-SNU-1 NV7sdnlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjJe41oUUN3ME2yOk42PDV2IN88US=> MUPTRW5ITVJ?
HH M{\3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLxUXZHUUN3ME2yOk42PTJ7IN88US=> NVXB[5k2W0GQR1XS
U-2-OS MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVexXo0xUUN3ME2yOk44Ozh{IN88US=> NXXRR402W0GQR1XS
SF539 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzFcGc{UUN3ME2yOk45ODF6IN88US=> NFe1PJdUSU6JRWK=
NCI-H2052 NG\TRYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\jTWM2OD1{Nz6wPFYh|ryP MUnTRW5ITVJ?
A673 NVqyVJZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTJ5LkKxNFIh|ryP NH3OZYFUSU6JRWK=
WM-115 Ml[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jK[mlEPTB;MkeuO|c3PyEQvF2= MUfTRW5ITVJ?
SW48 NH\2eJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfCNXpKSzVyPUK3MlgxODVizszN MWnTRW5ITVJ?
NOMO-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTJ5Lki1N|Ih|ryP MVXTRW5ITVJ?
PC-3 NUnFU2tJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LmeGlEPTB;MkeuPFk1OSEQvF2= M4[yTXNCVkeHUh?=
UMC-11 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnYXGJCUUN3ME2yO{46OzR|IN88US=> Mnv3V2FPT0WU
U-118-MG M3LHOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTJ6LkCxNlMh|ryP NYO2WFRRW0GQR1XS
NCI-H2452 NUP6fY0yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTJ6LkC4NlIh|ryP MWnTRW5ITVJ?
CAMA-1 M1qySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTJ6Lki1OlQh|ryP MVXTRW5ITVJ?
MC-IXC NUDTSFJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnm4TWM2OD1{OT6yN|Y3KM7:TR?= MofDV2FPT0WU
ES4 MmP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;VTWM2OD1{OT6zNVczKM7:TR?= Mk\hV2FPT0WU
BHT-101 NIH0V|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTJ7LkOyNUDPxE1? M37xVHNCVkeHUh?=
KP-4 NVzNOpBXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHaU5lTUUN3ME2yPU42OTZizszN M1XyZnNCVkeHUh?=
CAL-54 NEWwfppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo[3TWM2OD1{OT61OFQ2KM7:TR?= M3;PTnNCVkeHUh?=
5637 MlL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7vTWM2OD1{OT62OFIyKM7:TR?= M2mwenNCVkeHUh?=
MOLT-16 NV\RUWlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTJ7LkeyOlkh|ryP NUHLboN1W0GQR1XS
Ca-Ski MkjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1j5eGlEPTB;MkmuPVQ3KM7:TR?= MU\TRW5ITVJ?
AsPC-1 M4jXOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTNyLkCyNVIh|ryP Ml7LV2FPT0WU
MSTO-211H MkLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvEWlhKSzVyPUOwMlE2KM7:TR?= NVPCNG9lW0GQR1XS
L-428 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTNyLkSwOUDPxE1? NVzvPGJ4W0GQR1XS
SW1463 NV:3fYJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzY[YFKSzVyPUOwMlU{QDNizszN NGm3SXBUSU6JRWK=
NCI-H1648 Mnz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\mOGlEPTB;M{CuOVU4PCEQvF2= M{PCNnNCVkeHUh?=
CAKI-1 NU[xc4JLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3WTWM2OD1|MD63O|AzKM7:TR?= M1Tp[XNCVkeHUh?=
YKG-1 MnPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTNzLkCyOlMh|ryP Mn;SV2FPT0WU
A2058 M3XsXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTNzLkGxOlQh|ryP NIG0[mRUSU6JRWK=
A375 M3;CcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LjUGlEPTB;M{GuNVY6PiEQvF2= MVXTRW5ITVJ?
SNB75 NF7seIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPhSooyUUN3ME2zNU4zPDN3IN88US=> NWPtepBTW0GQR1XS
SK-HEP-1 M2HEPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfmTWM2OD1|MT60NlcyKM7:TR?= MXrTRW5ITVJ?
ME-180 NYXZdVdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTNzLk[1OFIh|ryP NV3NT5hxW0GQR1XS
NCI-H209 NXizNI5XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPBTWM2OD1|MT64NlQ4KM7:TR?= NVjVbYhSW0GQR1XS
HC-1 NVTkVWhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfOPIJFUUN3ME2zNk4yPDR4IN88US=> NVjOSYJIW0GQR1XS
LB373-MEL-D NX7UOWZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFS4SWlKSzVyPUOyMlE6PzFizszN MoLWV2FPT0WU
SNU-387 NELPboJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTN{LkOxPVEh|ryP NWnG[oJjW0GQR1XS
C32 NHzWXoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rWfWlEPTB;M{KuN|M2OyEQvF2= M1nkW3NCVkeHUh?=
EW-13 M{CwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLmd4hsUUN3ME2zNk46PDB6IN88US=> M2PnTnNCVkeHUh?=
BFTC-905 M3TWb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTN|LkWxN|Yh|ryP M{\nUHNCVkeHUh?=
NCI-H1299 MoP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfBVHVKSzVyPUOzMlU3OjFizszN NGrXbllUSU6JRWK=
LU-135 NF;SZWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TLXWlEPTB;M{OuPFAyKM7:TR?= MX7TRW5ITVJ?
NCI-H2122 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPJOZZuUUN3ME2zN{46QTZ4IN88US=> M1PQPHNCVkeHUh?=
SK-LMS-1 NV\CdIF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTN2LkSxNFch|ryP M1n2WnNCVkeHUh?=
LNCaP-Clone-FGC NIn6eHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTN2Lki1NVUh|ryP MkjKV2FPT0WU
NCI-H1092 M4TzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHFelZKSzVyPUO1MlI4PDdizszN NW\oR|JtW0GQR1XS
MS-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIX5[mdKSzVyPUO1MlMxOzhizszN MnPwV2FPT0WU
KYSE-510 M4HXVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnjR5JKSzVyPUO1MlUxPDJizszN MoXVV2FPT0WU
NCI-H1793 NIDKfFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXvTWM2OD1|NT62OVQ2KM7:TR?= MkjwV2FPT0WU
MIA-PaCa-2 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWT2XGRUUUN3ME2zOk4xPDl4IN88US=> MW\TRW5ITVJ?
EW-22 NIfhcZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljDTWM2OD1|Nj60NFczKM7:TR?= NUS2R2x3W0GQR1XS
IGR-1 NEfpT3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\sTWM2OD1|Nj64NVg1KM7:TR?= M{HaXHNCVkeHUh?=
HT-1080 M2PIe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2P4W2lEPTB;M{euNVI2KM7:TR?= NYnHTYJbW0GQR1XS
M14 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTN5LkG2OFIh|ryP NYX6cWEyW0GQR1XS
786-0 M2PaS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrETWM2OD1|Nz6yO|k1KM7:TR?= NHn5VoZUSU6JRWK=
MZ2-MEL M3LOdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\1NWlEPTB;M{euOFUxOSEQvF2= MXTTRW5ITVJ?
NCI-H510A NXTYTYx4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTN5Lkm0NVIh|ryP MmfLV2FPT0WU
LAN-6 M2fRUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjZfI5xUUN3ME2zO{46PTh{IN88US=> M4jLUXNCVkeHUh?=
SW620 M3fUS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTN6LkS5O|Qh|ryP NF;SRVRUSU6JRWK=
LB2241-RCC NWraTGZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1:4T2lEPTB;M{muPFIxPSEQvF2= NV;VWm5XW0GQR1XS
Detroit562 Mo[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1uwemlEPTB;NECuNVI3QCEQvF2= MWfTRW5ITVJ?
HN MlnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLrXpJ2UUN3ME20NE4yPzh{IN88US=> NWP6T3FuW0GQR1XS
HCT-15 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\UPGlEPTB;NECuOVkxPyEQvF2= NIPHc2RUSU6JRWK=
C2BBe1 Mn;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37mZmlEPTB;NECuPVE2PyEQvF2= M3T5eHNCVkeHUh?=
A498 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;OOVdVUUN3ME20NU4{ODF3IN88US=> MnXPV2FPT0WU
SK-MEL-24 NFH3W3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfVcIlKSzVyPUSxMlQ4OjVizszN M4e4S3NCVkeHUh?=
OVCAR-5 MoX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTRzLke3Olch|ryP NHT5PINUSU6JRWK=
NCI-H1792 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTRzLkm4NlEh|ryP MknzV2FPT0WU
KOSC-2 MlPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4S0emlEPTB;NEKuNlY6QSEQvF2= M4jXOXNCVkeHUh?=
Mo-T MkX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGn1O4JKSzVyPUSyMlg6PThizszN NVT1RXNpW0GQR1XS
CFPAC-1 NVrDfm9wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInLNFhKSzVyPUSzMlQ6PDRizszN MYPTRW5ITVJ?
CAL-51 M1TnTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTR|LkW2NFUh|ryP MV7TRW5ITVJ?
RH-18 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTR|LkiwOUDPxE1? NUX3NGJsW0GQR1XS
EC-GI-10 NVvHXmY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37FXWlEPTB;NEOuPFM1PyEQvF2= MVvTRW5ITVJ?
HSC-2 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfMTWM2OD12ND6wNFkh|ryP MXfTRW5ITVJ?
ML-2 M4PIVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTR3LkK2NlEh|ryP M1r4c3NCVkeHUh?=
KNS-81-FD MnW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojHTWM2OD12NT63N|Y2KM7:TR?= NHXTVWdUSU6JRWK=
NB6 NGnFV2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIj5[pdKSzVyPUS2MlEyOSEQvF2= NIfM[nhUSU6JRWK=
MCF7 NXroeJl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFntSGxKSzVyPUS2MlU2OzNizszN NF;Bc4RUSU6JRWK=
P30-OHK MnzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7FVm9KSzVyPUS2MlgyOTdizszN MkPJV2FPT0WU
BPH-1 NXfr[GxlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXjbJZKSzVyPUS2Mlk5ODVizszN MkfJV2FPT0WU
U251 Ml7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTR4Lkm5OEDPxE1? Mm\6V2FPT0WU
MKN1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVix[oc4UUN3ME20O{42OTN5IN88US=> NXvXPFI3W0GQR1XS
A431 NVXEcZVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXraXnF5UUN3ME20O{45OzN6IN88US=> NXjh[|FrW0GQR1XS
C8166 M3HFOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3ZNFNKSzVyPUS5MlIxOzlizszN M3LOXXNCVkeHUh?=
HEL MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;rTWM2OD12OT60NFY1KM7:TR?= M4fwXnNCVkeHUh?=
RMG-I NGnMZ5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nYeWlEPTB;NEmuOFQ1PCEQvF2= MXzTRW5ITVJ?
CAL-72 NY\x[IdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17FNWlEPTB;NEmuOlA4PSEQvF2= MVrTRW5ITVJ?
SW962 MnTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2G0N2lEPTB;NEmuPVM{OiEQvF2= MY\TRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Axitinib exhibits primary inhibition to orthotopically transplanted models such as M24met (melanoma), HCT-116 (colorectal cancer), and SN12C (renal cell carcinoma). [1] Axitinib delays the tumor growth with 11.4 days compared to the controls (p.o. 30 mg/kg) and decreases the Mean Vessels Density (MVD) to 21, compared to 49 in controls, in IGR-N91 flank xenografts. [2] Axitinib significantly inhibits growth and disrupts tumor microvasculature in BT474 breast cancer model at 10-100 mg/kg. [3] Axitinib has shown single-agent activity in variable tumors, including renal cell carcinoma, thyroid cancer, non-small cell lung cancer, and melanoma.

Protocol

Kinase Assay
+ Expand

Cellular receptor kinase phosphorylation assay:

Porcine aorta endothelial (PAE) cells, which overexpress full-length VEGFR2, PDGFRβ, Kit, and NIH-3T3, which overexpress murine VEGFR2 (Flk-1) or PDGFRα, are generated. The 96-well plates are coated with 100 μL/well of 2.5 μg/mL anti-VEGFR2 antibody, 0.75 μg/mL anti-PDGFRβ antibody, 0.25 μg/mL anti-PDGFRα antibody, 0.5 μg/mL anti-KIT antibody, or 1.20 μg/mL anti-Flk-1 antibody to prepare ELISA capture plates. Then phosphorylation of RTK is measured by ELISA.
Cell Research
+ Expand
  • Cell lines: HUVEC, SH-SY5Y, IGR-N91 and IGR-NB8 cells
  • Concentrations: 1 nM - 10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are seeded in a 96-well plate at a density of 5 × 104 and cultured for 24 hours. Axitinib is added to the cells at concentrations ranging from 1 nM to 10 μM. Cell viability is measured after 72 hours by MTS tetrazolium substrate and IC50 values are calculated.


    (Only for Reference)
Animal Research
+ Expand
  • Animal Models: BT474 breast cancer cells are implanted subcutaneously into Immune-deficient female mice (Nu/nu; age 8-12 weeks).
  • Formulation: 0.5% carboxymethylcellulose (CMC)
  • Dosages: 10, 30 or 100 mg/kg
  • Administration: Oral daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 35 mg/mL (90.56 mM) warming
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 0.5% CMC 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 386.47
Formula

C22H18N4OS

CAS No. 319460-85-0
Storage powder
in solvent
Synonyms AG 013736

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02156895 Not yet recruiting Advanced Renal Cell Carcinoma Pfizer December 2016 --
NCT02782403 Not yet recruiting Leukemia M.D. Anderson Cancer Center|Pfizer August 2016 Phase 1|Phase 2
NCT02762513 Not yet recruiting Squamous Cell Carcinoma of the Head and Neck University of Michigan Cancer Center May 2016 Phase 2
NCT02684006 Recruiting Renal Cell Cancer Pfizer March 2016 Phase 3
NCT02636725 Recruiting Alveolar Soft Part Sarcoma|Soft Tissue Sarcomas Breelyn Wilky|Merck Sharp & Dohme Corp.|Pfizer|University of Miami March 2016 Phase 2
NCT02693535 Recruiting Lymphoma, Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors American Society of Clinical Oncology|AstraZeneca|Bayer|Bristol-Myers Squibb|Eli Lilly and Company|Genentech, Inc.|Merck Sharp & Dohme Corp.|Pfizer March 2016 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    We would like to store at -80℃ after it dissolved in CMC. Do you have any infomation about the suggested concentration in CMC?

  • Answer:

    Axitinib in 0.5% CMC at up to 30mg/ml is a suspension for oral gavage administration only. We don't suggest customer to freeze down the solution but to make fresh if possible. Customer can store it for 1-2 weeks at 4 degree for continuous use.

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Axitinib | Axitinib supplier | purchase Axitinib | Axitinib cost | Axitinib manufacturer | order Axitinib | Axitinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID